Chardan Capital Has Optimistic View of TNYA FY2025 Earnings

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Research analysts at Chardan Capital upped their FY2025 earnings per share (EPS) estimates for Tenaya Therapeutics in a report issued on Monday, March 24th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings of ($0.71) per share for the year, up from their prior forecast of ($1.10). Chardan Capital has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Tenaya Therapeutics' current full-year earnings is ($1.35) per share.

Several other research firms have also weighed in on TNYA. HC Wainwright restated a "buy" rating and set a $5.00 target price on shares of Tenaya Therapeutics in a report on Monday. Morgan Stanley lowered their price objective on Tenaya Therapeutics from $15.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, March 12th. Finally, Canaccord Genuity Group decreased their target price on Tenaya Therapeutics from $18.00 to $6.00 and set a "buy" rating for the company in a research report on Thursday, March 13th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Tenaya Therapeutics presently has a consensus rating of "Buy" and an average target price of $6.25.

Tenaya Therapeutics Stock Down 5.4 %

Shares of TNYA traded down $0.03 during mid-day trading on Thursday, hitting $0.61. 1,430,819 shares of the company's stock were exchanged, compared to its average volume of 2,135,933. Tenaya Therapeutics has a twelve month low of $0.39 and a twelve month high of $5.25. The firm has a fifty day moving average of $0.90 and a two-hundred day moving average of $1.68. The stock has a market cap of $53.25 million, a price-to-earnings ratio of -0.42 and a beta of 2.83.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. State Street Corp increased its holdings in shares of Tenaya Therapeutics by 0.9% in the third quarter. State Street Corp now owns 1,058,898 shares of the company's stock valued at $2,044,000 after purchasing an additional 9,506 shares in the last quarter. Synovus Financial Corp acquired a new stake in shares of Tenaya Therapeutics in the 3rd quarter valued at $28,000. SG Americas Securities LLC increased its stake in shares of Tenaya Therapeutics by 61.9% in the 4th quarter. SG Americas Securities LLC now owns 41,270 shares of the company's stock valued at $59,000 after buying an additional 15,777 shares during the period. XTX Topco Ltd raised its position in shares of Tenaya Therapeutics by 51.2% during the third quarter. XTX Topco Ltd now owns 49,290 shares of the company's stock worth $95,000 after acquiring an additional 16,687 shares during the last quarter. Finally, Atticus Wealth Management LLC lifted its stake in shares of Tenaya Therapeutics by 56.3% during the fourth quarter. Atticus Wealth Management LLC now owns 47,762 shares of the company's stock valued at $68,000 after acquiring an additional 17,199 shares during the period. Institutional investors own 90.54% of the company's stock.

Insider Activity at Tenaya Therapeutics

In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III purchased 35,714,284 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was purchased at an average price of $0.70 per share, for a total transaction of $24,999,998.80. Following the completion of the purchase, the insider now directly owns 49,313,559 shares in the company, valued at approximately $34,519,491.30. This trade represents a 262.62 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 19,621 shares of company stock worth $10,595. 32.76% of the stock is owned by corporate insiders.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.